Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Principia Biopharma to Collaborate on Clinical Trial

NEW YORK (GenomeWeb) – Guardant Health and Principia Biopharma plan to collaborate on clinical trials for cancer therapies, the firms said today.

The pharmaceutical company will use Guardant Health's circulating tumor DNA assay, Guardant360, to monitor patients enrolled in a clinical trial for Principia's FGFR inhibitor, PRN1371, which is being developed for multiple indications.

The companies will use the Guardant360 assay, which assesses 70 genes from cell-free DNA to genomically profile patients' tumors and assess how they change in response to the drug.

The assay "gives us an opportunity to track tumor genetic alterations over time, and to evaluate the effects of Principia’s highly targeted FGFR therapy in our phase 1 clinical trial," Principia CEO Martin Babler said in a statement.

The collaboration with Principia is the second collaboration with a pharmaceutical company that Guardant has publicly announced. Last December, it said it would collaborate with Mirati Therapeutics to use its assay to screen lung cancer patients eligible for a phase 2 clinical trial of glesatinib, and that the collaboration could potentially result in a regulatory submission of Guardant360 as a companion diagnostic.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.